Key Takeaways JNJ filed an NDA for icotrokinra to treat moderate-to-severe plaque psoriasis in patients 12 and older. Icotrokinra met key endpoints in four phase III studies, showing significant skin clearance and safety. JNJ is testing icotrokinra against Stelara to offer a convenient oral alternative for plaque psoriasis.Johnson & Johnson (JNJ) announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its investigational oral peptide, icotrokinra, for treating moderate ...